Document Detail


Treatment of bipolar depression, a review of the literature and a suggestion for an algorithm.
MedLine Citation:
PMID:  11093064     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A review of the methodology and results of 9 controlled studies on the acute treatment of bipolar depression and the risk of switches into (hypo)mania is presented. There are indications but no proof for efficacy of mood stabilizers such as lithium, carbamazepine and valproate. Only lamotrigine has been shown to be effective, with a relative low risk of switching. Several antidepressants appear effective as well, but again there is no (placebo-controlled) proof of their efficacy. The only exception is tranylcypromine which has been found to be more effective than imipramine. The switch ratio into (hypo)mania by tricyclic antidepressants seems to be higher than by several other antidepressants, especially the selective serotonin reuptake inhibitors. In the acute treatment of bipolar depression, it is recommended to start with a mood stabilizer, and to add an antidepressant after 4-6 weeks in case of nonresponse. In severer cases, one might consider to start earlier with the combination of a mood stabilizer and an antidepressant, and in refractory patients, there is a place for tranylcypromine. In the maintenance treatment, there are indications that the combined treatment of a mood stabilizer (mostly lithium) and an antidepressant (TCA) is associated with an increased risk of switches into (hypo)mania, when compared to a mood stabilizer alone. Therefore, it is recommended to try whether a monotherapy with a mood stabilizer is effective, before combining it with an antidepressant.
Authors:
W A Nolen; D Bloemkolk
Related Documents :
17900204 - Limitations of contemporary antidepressants: tolerability.
14704834 - Time course of clinical response to venlafaxine: relevance of plasma level and chirality.
492044 - Effect of mianserin on cardiac conduction.
7580274 - Thyroid hormone treatment of depression.
14629244 - Single-site botulinum toxin type a injection for elimination of migraine trigger points.
12612984 - Health-related quality of life and associated outcomes among hemodialysis patients of d...
Publication Detail:
Type:  Journal Article; Meta-Analysis    
Journal Detail:
Title:  Neuropsychobiology     Volume:  42 Suppl 1     ISSN:  0302-282X     ISO Abbreviation:  Neuropsychobiology     Publication Date:  2000  
Date Detail:
Created Date:  2001-02-05     Completed Date:  2001-02-08     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7512895     Medline TA:  Neuropsychobiology     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  11-7     Citation Subset:  IM    
Copyright Information:
Copyright 2000 S. Karger AG, Basel.
Affiliation:
University Medical Centre Utrecht, The Netherlands. w.nolen@psych.azu.nl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Algorithms*
Antidepressive Agents / therapeutic use*
Antidepressive Agents, Tricyclic / therapeutic use
Antimanic Agents / therapeutic use
Bipolar Disorder / drug therapy*
Depressive Disorder / drug therapy*
Humans
Lithium / therapeutic use
Serotonin Uptake Inhibitors / therapeutic use
Chemical
Reg. No./Substance:
0/Antidepressive Agents; 0/Antidepressive Agents, Tricyclic; 0/Antimanic Agents; 0/Serotonin Uptake Inhibitors; 7439-93-2/Lithium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Differential efficacy of lithium and carbamazepine in the prophylaxis of bipolar disorder: results o...
Next Document:  Association studies of candidate genes in bipolar disorders.